EP2700403A1 — Therapeutic agent for tumor
Assigned to Eisai R&D Management Co Ltd · Expires 2014-02-26 · 12y expired
What this patent protects
A therapeutic agent for tumor for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound represented by Formula (II): wherein R 1 is C 1-6 alkyl or C 3-8 cycloalkyl, R 2 is a hydrogen atom or C 1-6 alkoxy, and R…
USPTO Abstract
A therapeutic agent for tumor for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound represented by Formula (II): wherein R 1 is C 1-6 alkyl or C 3-8 cycloalkyl, R 2 is a hydrogen atom or C 1-6 alkoxy, and R 3 is a hydrogen atom or a halogen atom, exhibits an excellent antitumor effect compared to cases where these are individually used.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.